學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Challenges in Commercial Deployment of AI: Insights from The Rise and Fall of IBM Watson's AI Medical System
內容大綱
When IBM set about commercializing its artificial intelligence-driven Watson AI in the healthcare market, its early successes were widely publicized. Senior managers and the media claimed that its diagnostic features would soon surpass those of the sharpest doctors. The case describes the large gap between what was promised and what happened in practice, offering insider insights on why IBM's projects failed. As the corporate commitment to AI escalated in response to successful lab results, cognitive dissonance arose between managers' expectations and what they could actually deliver. How could that have happened? Three reasons for Watson's downfall are explored: 1) The tendency for societal expectations to exceed the actual technical capabilities, leading to a gap in perception between AI in the lab and AI in the field. 2) Overselling of the economic benefits of AI by the salesforce; 3) Failure to secure the cooperation of key stakeholders, notably doctors who were asked to improve the performance of AI but were undermined by claims that AI could outperform them.